Individualized survival curves improve satisfaction with cancer risk management decisions in women with BRCA1/2 mutations.

PURPOSE Women with BRCA1/2 mutations are faced with complex decisions about breast and ovarian cancer risk management. This study was conducted to determine the effect of a tailored decision support system (DSS) that provides individualized survival and cancer incidence curves specific to expected outcomes of alternative management strategies. PATIENTS AND METHODS This was a double-blind, randomized controlled trial of 32 women with BRCA1/2 mutations. Primary outcome measures were decision satisfaction, cancer anxiety, perceptions of cancer risk given alternative management strategies, and management decisions. RESULTS Twenty-seven women completed a 6-week follow-up. Women in the intervention arm (n = 13) reported significantly higher decision satisfaction at follow-up than women in the control arm (n = 14; adjusted mean difference, 9.7; P < .0005). The effect of the DSS was greater among women with low cancer anxiety at baseline than women with high cancer anxiety at baseline (P = .01 for interaction). However, the DSS did not significantly alter cancer anxiety at follow-up, perceptions of cancer risk given alternative management strategies, or management decisions. CONCLUSION The presentation of individualized survival and incidence curves for alternative management options improves satisfaction about cancer risk management decisions among women with BRCA1/2 mutations without increasing anxiety or changing management decisions. The benefit of the DSS is greatest among women with relatively low cancer-related anxiety at baseline.

[1]  E. Winer,et al.  A review of hereditary breast cancer: from screening to risk factor modification. , 1997, The American journal of medicine.

[2]  A. O'Connor.  Validation of a Decisional Conflict Scale , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  P M Bossuyt,et al.  Decision support for patients with early-stage breast cancer: effects of an interactive breast cancer CDROM on treatment decision, satisfaction, and quality of life. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Michael J Green,et al.  Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. , 2004, JAMA.

[5]  H. Jick,et al.  Tamoxifen and risk of idiopathic venous thromboembolism. , 1998, British journal of clinical pharmacology.

[6]  Katrina Armstrong,et al.  Effect of Framing as Gain versus Loss on Understanding and Hypothetical Treatment Choices: Survival and Mortality Curves , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  Robert J Cersosimo,et al.  Tamoxifen for Prevention of Breast Cancer , 2003 .

[8]  M. Holmes-Rovner,et al.  Patient Satisfaction with Health Care Decisions , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  C. Tropé,et al.  Some aspects of prophylactic oophorectomy and ovarian carcinoma. , 1981, Annales chirurgiae et gynaecologiae.

[10]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[11]  Katrina Armstrong,et al.  Using survival curve comparisons to inform patient decision making , 2001, Journal of General Internal Medicine.

[12]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[13]  V. Entwistle,et al.  Decision aids for patients facing health treatment or screening decisions: systematic review , 1999, BMJ.

[14]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[15]  Gallagher Sm.  Rethinking access in an information age. , 1999 .

[16]  Dawn Stacey,et al.  Development and evaluation of a breast cancer prevention decision aid for higher‐risk women , 2003, Health expectations : an international journal of public participation in health care and health policy.

[17]  A. LaCroix,et al.  Breast cancer and hormone replacement therapy , 1997, The Lancet.

[18]  P. Newcomb,et al.  Hormone replacement therapy in relation to breast cancer. , 2002, JAMA.

[19]  A. Gafni,et al.  A Bedside Decision Instrument To Elicit a Patient's Preference Concerning Adjuvant Chemotherapy for Breast Cancer , 1992, Annals of Internal Medicine.

[20]  R. Lipman,et al.  Dimensions of symptom distress in anxious neurotic outpatients. , 1969, Psychopharmacology bulletin.

[21]  W. Daal,et al.  Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Peter Tugwell,et al.  Randomized Trial of a Portable, Self-administered Decision Aid for Postmenopausal Women Considering Long-term Preventive Hormone Therapy , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[23]  D. Torgerson,et al.  Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. , 2001, JAMA.

[24]  B. Weber,et al.  Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. , 2004, Journal of Clinical Oncology.

[25]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[26]  Lisa M. Schwartz,et al.  The Role of Numeracy in Understanding the Benefit of Screening Mammography , 1997, Annals of Internal Medicine.

[27]  Celette Sugg Skinner,et al.  Pre-counseling education materials for BRCA testing: does tailoring make a difference? , 2002, Genetic testing.

[28]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[29]  A. Ash,et al.  Measuring patients’ desire for autonomy , 2007, Journal of General Internal Medicine.

[30]  S. Seal,et al.  Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Robert M. Kaplan,et al.  A randomized controlled trial comparing internet and video to facilitate patient education for men considering the prostate specific antigen test , 2003, Journal of General Internal Medicine.

[32]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[33]  R. Theriault,et al.  Estrogen-replacement therapy in younger women with breast cancer. , 1994, Journal of the National Cancer Institute. Monographs.

[34]  I. Hickie,et al.  Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer , 2001, Psycho-oncology.

[35]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[36]  Daniel S. Weiss,et al.  The Impact of Event Scale: Revised , 2007 .

[37]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[38]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[39]  D. Gustafson,et al.  Effect of computer support on younger women with breast cancer , 2001, Journal of General Internal Medicine.

[40]  Amiram Gafni,et al.  Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. , 2004, JAMA.

[41]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[42]  B. Ponder,et al.  Prophylactic oophorectomy in inherited breast/ovarian cancer families. , 1995, Journal of the National Cancer Institute. Monographs.

[43]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[44]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.